The results indicated that NSCLC patients harboring EGFR L858R mutations tended to have a higher frequency of positive PD-L1 expression compared to those harboring EGFR Ex19del mutations (OR = 1.51; 95% CI: 1.10–2.08; P = 0.01; Figure 2B). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.